AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02359981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyBehavior
Description: The intervention automatically provides personalized suggestions based on users behavior and user context. Suggestions relates to users life and how often they have done them in the past. Since the suggestions relate to users' lives, they are easy to follow.
Study NCT02359981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic suggestions
Description: A nutritionist and an exercise trainer jointly created 45 food and exercise suggestions based on guidelines posted by the NIH. These suggestions ask users to walk for 30 minutes or eat healthier foods. These suggestions however doesn't personalize to users daily behavior into account.
Study NCT03929887 — intervention group
Intervention type: OTHER
Intervention: Kidney Biopsy
Description: Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core and various patient-derived samples.
Study NCT00707798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A
Description: Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested
Study NCT00707798 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23™
Description: One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2
Study NCT01451645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine (Colcrys®)
Description: daily 0.6 mg colchicine dosing for 16 weeks
Study NCT01451645 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: daily placebo dosing for 16 weeks
Study NCT01451645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allopurinol
Description: background therapy
Study NCT01451645 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: allopurinol
Description: background therapy
Study NCT01692678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Type=exact number, unit=mg/m2, number=1.5, 1.2 or 1.0, form=solution, route=intravenous infusion. Trabectedin will be administered on Day 1 of each 21-day treatment cycle.
Study NCT01692678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Type=exact number, unit=g/m2, number=1, form=solution, route=intravenous infusion. Dacarbazine will be administered on Day 1 of each 21-day treatment cycle.
Study NCT01958645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8111
Description: MEDI8111 lyophilisate for solution for infusion
Study NCT01958645 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for MEDI8111 saline solution for infusion
Study NCT04244565 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self-directed model of clinical learning for nurses
Description: the instructors play a facilitating role while, learners actively participate in identifying their own learning needs, learning goals, allocating resources \& decide whether learning method can be used, and engaging in self-reflection \& evaluation.
Study NCT01130571 — intervention group
Intervention type: PROCEDURE
Intervention: Xenografts and cell cultures
Study NCT02838173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: serratus plane bloc : Ropivacaine 2mg/ml (0,3ml/kg)
Study NCT02838173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tissue infiltration : Ropivacaine 2mg/ml (0,3ml/kg)
Study NCT02838173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: serratus plane bloc : placebo
Study NCT02838173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tissue infiltration : placebo
Study NCT01225562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg
Description: Oral dose twice a day
Study NCT01225562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Description: Oral dose twice a day
Study NCT01225562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor Placebo
Description: Oral dose twice a day
Study NCT02705898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LPA+Fitbit
Study NCT02705898 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HEC
Study NCT04408807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speculum-free (SpF) fundoscopy
Description: Indirect ophthalmoscopy without the use of eyelid speculum and scleral indentation
Study NCT04408807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speculum (Sp) fundoscopy
Description: Indirect ophthalmoscopy with the use of eyelid speculum and scleral indentation
Study NCT00805896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Songyou
Description: 4g/pack
Study NCT00805896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4g/pack
Study NCT01645267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite
Description: Use of artifical bonegraft material
Study NCT00364182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Coagulation Factor IX (BeneFIX)
Description: 100 IU/kg once weekly then crossover to 50 IU/kg twice weekly
Study NCT00364182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Coagulation Factor IX (BeneFIX)
Description: 50 IU/kg twice weekly then crossover to 100 IU/kg once weekly
Study NCT02431416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin releasing hormone (GnRH)
Description: Gonadotropin releasing hormone GnRH (Relefact LHRH) iv injection, single dose, 100 micrograms/square meter body surface, maximum dose: 100 microgram.
Study NCT02431416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Sodium chlorid 9 mg/mL will be given as a single iv injection with the same volume as the volume used for the active substance injection.
Study NCT01526525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol
Description: Tramadol 1.5mg/kg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of tramadol 0.15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®)
Study NCT01526525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol 1.5mg/kg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of tramadol 0.15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®)
Study NCT01526525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: ketamine 10mg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of ketamine, in subanesthetic doses, 0,15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®). Ketamine's dose was altered so as not to exceed the 300mg/24h.
Study NCT01526525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine 10mg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of ketamine, in subanesthetic doses, 0,15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®). Ketamine's dose was altered so as not to exceed the 300mg/24h.
Study NCT01526525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol
Description: If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients.The aim was that the Tramadol 24h dose would not exceed 600mg
Study NCT01526525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients.The aim was that the Tramadol 24h dose would not exceed 600mg
Study NCT01526525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients and if the NRS scale was not decreased at least about 2 points after 30 minutes, morphine 2mg IV was then administered and it could be repeated
Study NCT01526525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients and if the NRS scale was not decreased at least about 2 points after 30 minutes, morphine 2mg IV was then administered and it could be repeated
Study NCT01526525 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sedation
Description: If the patient had sedation score >2 then the analgesic infusion would be stopped, the patient would be assessed again in 1 hour and the infusion would start with the same or decreased flow.
Study NCT01526525 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sedation
Description: If the patient had sedation score >2 then the analgesic infusion would be stopped, the patient would be assessed again in 1 hour and the infusion would start with the same or decreased flow.
Study NCT01526525 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: rescue analgesia
Description: Meanwhile - 45min,2h,6h,12h and 24h- if the patients had acute pain, the physician would call the anesthesiologist and a new assessment would take place with the relative interventions.
Study NCT01526525 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rescue analgesia
Description: Meanwhile - 45min,2h,6h,12h and 24h- if the patients had acute pain, the physician would call the anesthesiologist and a new assessment would take place with the relative interventions.
Study NCT01526525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Parecoxib
Description: An hour before the end of the surgery all patients were administered with parecoxib 40mg (IV)
Study NCT01526525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parecoxib
Description: An hour before the end of the surgery all patients were administered with parecoxib 40mg (IV)
Study NCT01526525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paracetamol
Description: 30min before the end of the surgery paracetamol 20mg/kg (IV).
Study NCT01526525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 30min before the end of the surgery paracetamol 20mg/kg (IV).
Study NCT04106622 — intervention group
Intervention type: PROCEDURE
Intervention: electrophysiological study
Description: To assess whether the AP is of high risk or not, for all patients the AERP of the AP will be determined by one of the following ways:~The cycle length at which abrupt and complete loss of pre-excitation occurs during exercise test. If this didn't happen, the patient will be subjected to invasive electrophysiologic study..~The Antegrade refractory period of the AP is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP.~The shortest pre-excited R-R interval during spontaneous or induced AF.
Study NCT00899093 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study NCT00899093 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00147550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Description: Administered orally either once or twice a day; several dosing schedules evaluated; current dosing schedule is 5 days on-drug, 2-days off drug for 3 weeks in a 28-day cycle. Doses evaluated ranged from 1 mg once a day to 30 mg twice daily.
Study NCT02141477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.
Study NCT02141477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I.
Study NCT02205489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab GZ402673
Description: Pharmaceutical form:concentration for solution Route of administration: intravenous infusion
Study NCT02205489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetirizine
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02205489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranitidine
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02205489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02205489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Pharmaceutical form:solution Route of administration: intravenous
Study NCT04624425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmental breathing exercises
Description: Segmental breathing exercises along with the Conventional Treatment of buteyko breathing exercises for two weeks of duration. Segmental breathing exercises include 18-20 breaths in one session (6 breaths/min) with rest interval after every 6 breaths.
Study NCT04624425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Buteyko breathing exercises
Description: Buteyko exercises for two weeks of duration. Treatment session will be last for 10-15minutes.
Study NCT04635865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed patient-specific plate
Description: We adopt an in-house approach for designing by surgeons. All patient-specific devices are designed in 3-matic 13.0 (Materialise). Both cutting and transferring guides are then additively manufactured by Fused Deposition Manufacturing (FDM) using ULTEM 1010, or by Stereolithography using MED610 resin (Stratasys Ltd, Eden Prairie, MN, USA). Both ULTEM 1010 and MED610 are FDA cleared biocompatible materials applicable to high-temperature autoclaving.~Patient-specific surgical plates are designed by delineating a plate path on bone surface, then followed by the placement of screw holes. Surgical plates are generated by the built-in command in 3-matic. After that, surgical plates are fabricated by SLM using grade 2 titanium powder.
Study NCT04635865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional commercial reconstruction plate
Description: Bone segments will be stabilized using commercial titanium surgical plates (DePuy Synthes, United States), which are bent manually before fastening the screws.\[
Study NCT02979210 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Artificial Fecal Insult
Description: protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline
Study NCT02979210 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phosphate Buffered Saline
Description: 200 microliters of phosphate buffered saline
Study NCT02342132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive bipap ventilator
Description: The non-invasive bipap ventilator will be used in the following respiratory treatment: bipap assisted inspiratory breaths (BAIB). The patient will be encouraged to take deep breaths at least 1.5 times greater than resting tidal volume. The pressure assistance provided by the bipap starts at 10cm H2O. Patients already on bipap will use their home settings. Starting pressure is then increased as necessary to meet the maximal inspiratory goal volume in steps of 2 up to a maximum 20cm H2O. Once the ideal pressure of support levels are established, the child will perform 3 cycles of 5 deep breaths. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
Study NCT02342132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical insufflator-exsufflator
Description: A commercial mechanical insufflator-exsufflator will be used in the following treatment: Mechanical insufflation-exsufflation (MI-E). The pressure will be administered by a face mask. The optimal pressure for the test will start at 10 cm H2O and will in crease in steps of 5 to a maximum of 25 cm H2O. The insufflation phase will take 3 seconds followed by a 2 second exsufflation phase. Three cycles of treatment will be used. Between each cycle the subject will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
Study NCT02342132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency percussive oscillator
Description: A commercial high frequency percussive oscillator will be used in the following treatment: combined oscillation and nebulisation. Pressures will be delivered by a face mask. At higher oscillation frequencies it is usually necessary to support the cheeks. Pressure will be gradually be increased to accustom the child to a maximum of 25cm H2O. This standard maximal pressure will ideally be used for every child. A treatment cycle will consist of 3 minutes at a frequency of 2 Hz and pressure of 15cm H2O followed by 3 minutes of 4 Hz at 20cm H2O, then 3 minutes of 5 Hz at 25cm H2O. Throughout each cycle, the patient will receive nebulized saline through the machine. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
Study NCT02452762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Study NCT02452762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04070482 — intervention group
Intervention type: OTHER
Intervention: Tenofovir exposure in utero and during breastfeeding
Description: Exposed in utero and during breastfeeding to Tenofovir-containing antiretroviral drugs
Study NCT02530931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: diffusion of gadolinium for a population with Meniere's disease in order to develop an imaging disease screening test
Study NCT03595280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hookah tobacco risk messages
Description: Mobile multimedia messages consisting of text and imagery conveying the risks of hookah tobacco use.
Study NCT02890680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin
Study NCT02890680 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Study NCT04409938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
Study NCT02205489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aciclovir
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT04409938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature Sounds
Description: PMR+NS participants practiced PMR accompanied by nature sounds. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
Study NCT03629483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients in this group receive continuous femoral nerve block analgesia for 48 hours after surgery. The formula is a mixture of 0.2% ropivacaine 250ml and 3.75 ug/kg dexmedetomidine. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h (equivalent to a dexmedetomidine infusion at a rate of 0.075 ug/kg/h).
Study NCT03629483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group receive continuous femoral nerve block analgesia for 48 hours after surgery. The formula is a mixture of 0.2% ropivacaine 250 ml and placebo. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h.
Study NCT01238692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: Patients randomized to both arms will receive oral LBH589, once-a-day, at a dose of 30 mg/day, on a three times-a-week (Monday, Wednesday and Friday) schedule as part of a 3 week (21 day) treatment cycle. Day one of each cycle will be on a Monday.